Hassen Sayeed
`Partner
`
`New York
`D: +1-212-326-2136
`
`Los Angeles
`D: 213-430-6151
`
`San Francisco
`D: 415-984-8853
`hsayeed@omm.com
`
`Admissions
`
`Bar Admissions
`New York
`
`Court Admissions
`US District Court, Eastern and
`Southern Districts of New York
`US Court of Appeals, Federal Circuit
`US Supreme Court
`
`Education
`
`Harvard Law School, J.D.
`Brown University Medical School,
`M.D.
`Harvard College, A.B.
`
`Dr. Hassen Sayeed is an experienced trial lawyer and one of the
`few patent litigators in the United States with a medical degree.
`His practice focuses on representing innovator life sciences
`companies in contested matters involving pharmaceuticals,
`biotechnology, and medical devices. He has particular expertise
`in cases arising under the Hatch-Waxman Act and the Biologics
`Price Competition and Innovation Act.
`For nearly two decades, Hassen's unique background has given
`him valuable insight and unrivaled technical understanding in
`helping both domestic and international companies achieve their
`strategic goals. His dedication to client service and his legal
`acumen have been recognized by several publications. Hassen
`was named a "Life Sciences Star" for Hatch-Waxman patent
`litigation by LMG Life Sciences (2020). The Legal 500 named him
`a Recommended Lawyer for both Life Sciences (2019) and
`Patent Litigation (2019-2021), as well as a Next Generation
`Lawyer for Life Sciences (2021). IAM Patent 100 (2021) noted
`that Hassen attracts "glowing reviews," with clients saying that
`"Hassen is thorough and responsive, and achieves clients' goals
`even under immense time pressure. His work product is
`consistently excellent and he's brilliant at spotting tangential
`issues that ultimately are of importance."
`Hassen is a frequent speaker on developments in patent law and
`an active member of the IP community. He served as a Global
`Fellow of the Federal Circuit Bar Association in 2016-2017. He
`has also devoted significant efforts to pro bono work and has
`been a champion of increasing diversity and inclusion in the bar.
`
`O’Melveny & Myers LLP
`
`SERVIER-2006
`IPR2022-01423
`
`1
`
`

`

`•
`
`•
`
`Experience
`•
`Lead counsel for international pharmaceutical company on patents related to treatment of
`hematological cancers.
`Lead counsel for international pharmaceutical company on patents related to treatment of ovarian
`cancer.
`Lead counsel for international pharmaceutical company against multiple generic challengers on
`patents related to oral heart failure drug.
`• Co-lead counsel for international pharmaceutical company on patents related to treatment of irritable
`bowel syndrome.
`• Co-lead counsel for international pharmaceutical company on patents related to treatment of
`hypotrichosis.
`• Co-lead counsel for international pharmaceutical company on patents related to treatment of multiple
`myeloma.
`• Defended leading biologics company in BPCIA litigation relating to a biosimilar version of Humira®.
`• Represented leading Japanese pharmaceutical company against multiple generic challengers on
`patents concerning first-in-class diabetes compound.
`• Represented leading Japanese pharmaceutical company against multiple generic challengers on
`patents concerning treatment of benign prostatic hyperplasia.
`• Represented leading German innovator company in patent infringement cases involving methotrexate
`and autoinjector technology.
`• Represented leading German innovator company against multiple generic challengers on patents
`concerning topical corticosteroid cream.
`• Represented leading Japanese pharmaceutical company against multiple generic challengers on
`patents involving beta-blocker treatment for glaucoma.
`• Represented innovator pharmaceutical company in patent infringement action concerning patents
`directed to inhalation medication for the treatment of pediatric asthma.
`• Represented innovator pharmaceutical company in patent infringement action concerning patents
`directed to osteoarthritis treatment.
`• Represented leading pharmaceutical company against multiple generic challengers on patents
`concerning chemotherapy drug used to treat glioma.
`
`Professional Activities
`Member
`•
`American Medical Association
`•
`Federal Circuit Bar Association
`•
`Intellectual Property Owners Association (Pharmaceutical and Biotechnology Issues Committee;
`Women in IP Committee; Presidential Task Force on Diversity, Inclusion, and Leadership)
`• New York Intellectual Property Association
`
`O’Melveny & Myers LLP
`
`2
`
`

`

`• New Jersey Intellectual Property Association
`•
`South Asian Bar Association of North America
`• National Asian Pacific American Bar Association
`Moderator
`•
`“An In-House Perspective on Biologics/Biosimilars Litigation,” The New York Intellectual Property Law
`Association (February 2019)
`Publications
`• Co-author, “AI and Life Sciences Patents: Separating Myth From Reality,” New York Law Journal
`(March 20, 2020)
`• Co-author, “Intellectual Property Developments in Biochip Nanotechnology, 3 Nanotech Law & Bus. 1
`(2006)
`• Co-author, “New Developments: Financial Conflicts of Interest in Human Subjects Research,” 2 Med.
`Res. L. & Pol’y Rep. (BNA) 421 (June 4, 2003)
`Author, “Recent Developments in Health Law, Patient Confidentiality: Hospital’s Release of Alcohol
`Treatment Data Does Not Violate Regs,” 30 J.L. Med. & Ethics 133, 319 (2002)
`Author, “Recent Developments in Health Law, FMLA: Department of Labor Overstepped Authority,”
`30 J.L. Med. & Ethics 356, 462 (2002)
`• Mentioned, “Original-Patent Rule Dooms Drug Injection Complaint,” Law360 (November 17, 2014)
`• Mentioned, “Appeals court won’t stop Medac from selling injectable drug,” Reuters Legal (November
`17, 2014)
`• Mentioned, Law360's weekly "Legal Lions" list (May 7, 2020)
`Speaker
`•
`“Best Ways to Protect Your Innovation,” J&J’s Legal Webinar Series for Life Sciences Entrepreneurs
`(July 16, 2020)
`“What Can Medical Biotechnology Learn from Patent Litigation in Industrial and Agricultural Biotech?”
`Bio IP Counsels Committee Conference (November 14-16, 2018)
`“Life Sciences Overview 2017”, Practising Law Institute, 11th Annual Patent Law Institute, New York
`(April 7, 2017)
`“Ethical Considerations in Paragraph IV Practice,” American Conference Institute, Paragraph IV
`Disputes Conference, New York (April 25, 2016)
`“Ethical Considerations In Paragraph IV Practice: A Roadmap For 2016,” American Conference
`Institute, Paragraph IV Conference (April 26, 2016)
`“Inter Partes Reviews and U.S. Biopharma Litigation Strategy,” C5’s 8th Forum on Pharma & Biotech
`Patent Litigation 2016 (March 15, 2016)
`“Introduction To ANDA Litigation And Hot Topics For 2016,” Japan External Trade Organization
`Health Care Study Group (March 17, 2016)
`“Ariosa v. Sequenom: The End Of Precision Medicine?”, New York Pharma Forum (March 29, 2016)
`
`•
`
`•
`
`•
`
`O’Melveny & Myers LLP
`
`3
`
`•
`
`•
`
`•
`
`•
`
`•
`
`•
`
`

`

`•
`
`•
`
`•
`•
`
`•
`
`•
`
`•
`
`“Hatch-Waxman Litigation: Delisted Patents And Challenges To Personal Jurisdiction,” The
`Knowledge Group Webinar (January 2016)
`“Evolving Biosimilars Landscape: Opportunities and Challenges,” New York Pharma Forum (May 13,
`2015)
`“Hatch-Waxman Bootcamp,” Training Series (July 2015)
`“Pharmaceutical Brand Protection For Method Claims,” The Knowledge Group Webinar (August
`2015)
`“Establishing Personal and General Jurisdiction in A Paragraph IV Case,” American Conference
`Institute, Paragraph IV Conference Master Class (September 30, 2015)
`“Post-Grant Proceedings In Patent Litigation: Perspectives From Life Sciences & High Tech,”
`National Asian Pacific American Bar Association Annual Convention (2015)
`“Abbreviated New Drug Application (ANDA) with Paragraph IV Certification: Critical Insights in 2015 –
`Challenges To Personal Jurisdiction,” The Knowledge Group Webinar (2015)
`
`Honors & Awards
`• Recognized by IAM Patent 1000 (2020-2022)
`• Recognized by Best Lawyers® 2022 for Litigation - Patent in New York, NY; Hassen has been listed
`in Best Lawyers® since 2022
`• Named Life Sciences Star for Hatch-Waxman Patent Litigation by LMG Life Sciences (2020)
`• Recommended Lawyer for Life Sciences (2019) and Patent Litigation (2019-2021), and Next
`Generation Lawyer for Life Sciences (2021) by The Legal 500 US
`• Global Fellow, Federal Circuit Bar Association (2016-2017)
`•
`IP Litigation Rising Star, New York Super Lawyers (2014-2015)
`
`O’Melveny & Myers LLP
`
`4
`
`